ENTERA BIO LTD (ENTX) Fundamental Analysis & Valuation

NASDAQ:ENTX • IL0011429839

Current stock price

1.12 USD
+0.01 (+0.9%)
Last:

This ENTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ENTX Profitability Analysis

1.1 Basic Checks

  • ENTX had negative earnings in the past year.
  • ENTX had a negative operating cash flow in the past year.
  • In the past 5 years ENTX always reported negative net income.
  • In the past 5 years ENTX always reported negative operating cash flow.
ENTX Yearly Net Income VS EBIT VS OCF VS FCFENTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

  • ENTX has a worse Return On Assets (-61.93%) than 60.35% of its industry peers.
  • ENTX has a Return On Equity (-70.77%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -61.93%
ROE -70.77%
ROIC N/A
ROA(3y)-92.24%
ROA(5y)-87.81%
ROE(3y)-104.97%
ROE(5y)-103.66%
ROIC(3y)N/A
ROIC(5y)N/A
ENTX Yearly ROA, ROE, ROICENTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ENTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENTX Yearly Profit, Operating, Gross MarginsENTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. ENTX Health Analysis

2.1 Basic Checks

  • ENTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ENTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ENTX Yearly Shares OutstandingENTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ENTX Yearly Total Debt VS Total AssetsENTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • An Altman-Z score of 3.23 indicates that ENTX is not in any danger for bankruptcy at the moment.
  • ENTX's Altman-Z score of 3.23 is fine compared to the rest of the industry. ENTX outperforms 68.67% of its industry peers.
  • There is no outstanding debt for ENTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.23
ROIC/WACCN/A
WACC8.53%
ENTX Yearly LT Debt VS Equity VS FCFENTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

  • ENTX has a Current Ratio of 10.83. This indicates that ENTX is financially healthy and has no problem in meeting its short term obligations.
  • ENTX has a better Current ratio (10.83) than 83.37% of its industry peers.
  • ENTX has a Quick Ratio of 10.83. This indicates that ENTX is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 10.83, ENTX belongs to the best of the industry, outperforming 83.37% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.83
Quick Ratio 10.83
ENTX Yearly Current Assets VS Current LiabilitesENTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. ENTX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 44.00% over the past year.
EPS 1Y (TTM)44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-395.43%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENTX Yearly Revenue VS EstimatesENTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2024 2025 0 200K 400K
ENTX Yearly EPS VS EstimatesENTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2023 2024 2025 2026 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

0

4. ENTX Valuation Analysis

4.1 Price/Earnings Ratio

  • ENTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ENTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENTX Price Earnings VS Forward Price EarningsENTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENTX Per share dataENTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ENTX Dividend Analysis

5.1 Amount

  • No dividends for ENTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ENTX Fundamentals: All Metrics, Ratios and Statistics

ENTERA BIO LTD

NASDAQ:ENTX (4/1/2026, 1:02:10 PM)

1.12

+0.01 (+0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27
Earnings (Next)05-07
Inst Owners20.34%
Inst Owner Change1.63%
Ins Owners2.86%
Ins Owner Change3.29%
Market Cap51.36M
Revenue(TTM)N/A
Net Income(TTM)-10.78M
Analysts82.86
Price Target10.2 (810.71%)
Short Float %0.4%
Short Ratio0.79
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.14%
Min EPS beat(2)23.75%
Max EPS beat(2)46.52%
EPS beat(4)4
Avg EPS beat(4)70.19%
Min EPS beat(4)23.75%
Max EPS beat(4)184.03%
EPS beat(8)7
Avg EPS beat(8)32.3%
EPS beat(12)10
Avg EPS beat(12)25.72%
EPS beat(16)14
Avg EPS beat(16)25.06%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)12.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 414.22
P/FCF N/A
P/OCF N/A
P/B 3.37
P/tB 3.37
EV/EBITDA N/A
EPS(TTM)-0.14
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0
BVpS0.33
TBVpS0.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -61.93%
ROE -70.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-92.24%
ROA(5y)-87.81%
ROE(3y)-104.97%
ROE(5y)-103.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 244.12%
Cap/Sales 66.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.83
Quick Ratio 10.83
Altman-Z 3.23
F-Score5
WACC8.53%
ROIC/WACCN/A
Cap/Depr(3y)40.07%
Cap/Depr(5y)48.71%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y-395.43%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-5.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.54%
OCF growth 3YN/A
OCF growth 5YN/A

ENTERA BIO LTD / ENTX Fundamental Analysis FAQ

What is the fundamental rating for ENTX stock?

ChartMill assigns a fundamental rating of 2 / 10 to ENTX.


Can you provide the valuation status for ENTERA BIO LTD?

ChartMill assigns a valuation rating of 0 / 10 to ENTERA BIO LTD (ENTX). This can be considered as Overvalued.


Can you provide the profitability details for ENTERA BIO LTD?

ENTERA BIO LTD (ENTX) has a profitability rating of 0 / 10.


What is the financial health of ENTERA BIO LTD (ENTX) stock?

The financial health rating of ENTERA BIO LTD (ENTX) is 8 / 10.